Pentostatin
- Generic Name
- Pentostatin
- Brand Names
- Nipent
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 53910-25-1
- Unique Ingredient Identifier
- 395575MZO7
- Background
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
- Indication
For the treatment of hairy cell leukaemia refractory to alpha interferon.
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia (HCL), Mycosis Fungoides (MF), Sezary Syndrome, Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT05757310
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Blood Stem Cell Transplant for Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03249831
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT03112603
- Locations
- 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
🇷🇴Novartis Investigational Site, Bucharest, Romania
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 57
- Registration Number
- NCT03077542
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 56
- Registration Number
- NCT02105766
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Niguarda Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT01681563
- Locations
- 🇮🇹
IRCCS Policlinico San Matteo Pavia Istituto di Ematologia, Pavia, Italy
🇮🇹Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia, Brescia, Italy
🇮🇹Azienda Ospedaliera San Gerardo di Monza U.O. Ematologia, Monza, MB, Italy
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT01362790
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2018-05-25
- Target Recruit Count
- 10
- Registration Number
- NCT01352312
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT01188798
- Locations
- 🇺🇸
St . Jude Children's Research Hospital, Memphis, Tennessee, United States
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT01059786
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.